Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 10/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3646293 | 0.94 | HTR6 (0.50) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL17580937 | 0.87 | HTR2A (0.47) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3646882 | 0.86 | HTR6 (0.54) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL13359008 | 0.85 | HTR6 (0.67) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3651450 | 0.84 | HTR6 (0.71) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL3647127 | 0.84 | HTR6 (0.66) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3643424 | 0.84 | HTR6 (0.58) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3750029 | 0.83 | HTR6 (0.47) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL17580974 | 0.83 | HTR2A (0.46) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL17580778 | 0.83 | PIM1 (0.49) | HTR6PIM1NAMPTAKR1C3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185555-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2016-03-16 | — | — | EP | claimed |
| US-8440694-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | claimed |
| US-8293913-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-10-23 | — | — | US | claimed |
| EP-2185555-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8440694-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20130005703-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8293913-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20100292271-A1 | Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-2185555-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009019286-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292271-A1 | Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor | HTR6, HTR1A, HTR3B | HTR6 1/4885HTR2A 7/4885HTR1A 2/4885 |
| US-20130005703-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR | HTR6, HTR1A, HTR3B | HTR6 1/4885HTR2A 7/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.